Filing Flows › CareDx (CDNA) › Guidance & outlook

CareDx (CDNA) guidance and outlook

CareDx (CDNA) raised its guidance on Oct 29, 2026: Revenue $520M–$530M for FY2026; EBITDA $90.0M–$100M for FY2026.

Guidance and outlook

Met or beat 2 of 2 guided periods. Grey: the last range guided before the figures came out; dot: the reported figure.

Latest guidance

Metric	Period	Range	Change
Revenue	FY2026	$520M–$530M	raised
EBITDA	FY2026	$90.0M–$100M	raised

From the earnings release filed Oct 29, 2026 (8-K on EDGAR).

CareDx's latest quarter

CareDx, Q3 2026: revenue $139M (+39% year over year), operating margin 5.8%, net earnings $19.3M, operating cash flow $12.7M. The chart follows the revenue to costs, profit and cash.

Questions

Did CareDx raise or lower its guidance?

CareDx (CDNA) raised its guidance on Oct 29, 2026: Revenue $520M–$530M for FY2026; EBITDA $90.0M–$100M for FY2026.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.